Biostage CEO David Green made permanent; new agreement includes $300k salary, stock options
Harvard Apparatus Regenerative Technology, Inc.
Interim tag removed; David Green named permanent CEO effective January 11, 2023.
Annual base salary set at $300,000; cash incentive up to 100% of base salary.
Initial stock option grants: $200k Black-Scholes value (monthly vesting over 12 months); fully vested option for $200k; LTI grant of 6% of outstanding shares (36-month vesting).
Severance: $300,000 cash plus $200k Black-Scholes option if terminated without cause or for good reason.
HRGN ·
Harvard Apparatus Regenerative Technology, Inc.
Effective
2023-01-11
Filed
January 12, 2023, 6:59 PM ET
Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
David Green changed role as Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
Action
removed Interim designation
Role
Chief Executive Officer
Exact text from the filing
Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.